SIGLEC8 Antibody

What is Siglec-8 and what cell types express it?

Siglec-8 (Sialic acid-binding immunoglobulin-like lectin 8) is a CD33-related Siglec family member selectively expressed on human mast cells and eosinophils, with lower expression levels on basophils. Quantitative analysis has revealed approximately 18,000-22,000 Siglec-8 receptors per cell on both eosinophils and mast cells, while basophils express significantly fewer receptors (approximately 500 receptors/cell) . Siglec-8 was discovered in 2000 through random high-throughput EST sequencing of a cDNA library from a subject with hypereosinophilic syndrome . The receptor contains inhibitory signaling domains that can modulate immune cell function when engaged.

How stable is Siglec-8 expression across different disease states and tissue compartments?

Unlike other receptors such as IL-5Rα, Siglec-8 expression remains remarkably stable between blood and tissue compartments, making it continuously targetable by antibodies regardless of cellular location . Research has demonstrated consistent Siglec-8 expression levels on eosinophils across various inflammatory conditions including hypereosinophilic syndrome (HES), asthma, eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and systemic mastocytosis (SM) . Importantly, treatment with medications such as prednisone or imatinib does not significantly alter Siglec-8 expression levels on blood eosinophils, despite causing substantial decreases in absolute eosinophil counts . This expression stability across disease states and treatment conditions makes Siglec-8 a reliable target for therapeutic intervention.

What are the methodological considerations for assessing Siglec-8 expression?

Flow cytometry represents the gold standard for evaluating Siglec-8 expression, though researchers should be cautious about antibody selection. Studies have identified specificity differences between commercially available Siglec-8 antibodies due to sequence similarities among CD33-related family members . Using a Siglec-based cross-reactive ELISA, researchers determined that Siglec-8 mAb clones FAB7975 (R&D Systems) and 347104 (Biolegend) bind specifically to Siglec-8, whereas clone HPA012556 (Sigma and Atlas) cross-reacts with multiple Siglecs, including Siglec-9, -7, and -12 . For accurate expression assessment, researchers should:

• Use verified Siglec-8-specific antibody clones

• Include appropriate isotype controls

• Incorporate viability dyes (e.g., DAPI) when working with eosinophils due to their propensity for spontaneous apoptosis

• Consider combining surface marker analysis with quantitative PCR for comprehensive expression profiling

What experimental models exist for studying Siglec-8 function?

Several experimental models have been developed to study Siglec-8 biology:

• Transgenic mouse models: Various transgenic mouse strains express Siglec-8 on specific immune cell populations through cell-specific or cell-selective Cre expression systems that remove a STOP cassette .

• SIGLEC8Eo strain: This model has been crossed with Siglec-F null strains to create mice that express Siglec-8 but not Siglec-F (the murine functional paralog) .

• Humanized immune system mice: NSG-SGM3 mice engrafted with human thymus, liver, or hematopoietic stem cells that express SCF, GM-CSF, and IL-3 generate human mast cells and eosinophils expressing functional Siglec-8 .

• In vitro cell culture systems: Primary human eosinophils purified from peripheral blood and human skin-derived mast cells can be used to evaluate Siglec-8 function in controlled experimental conditions .

These models provide complementary approaches for testing antibodies and glycomimetics that preferentially bind to Siglec-8, determining their targeting specificity, and assessing functional outcomes in relevant cellular contexts.

What mechanisms underlie Siglec-8 antibody-induced cell death in eosinophils?

The mechanisms of Siglec-8 antibody-induced eosinophil death involve complex signaling pathways that vary depending on cellular priming status:

• In unprimed eosinophils:

  • Extensive antibody crosslinking is required to induce cell death

  • The process is primarily caspase-dependent

  • Secondary crosslinking with anti-mouse antibody is necessary

  • Cell death induction is limited without cytokine priming

• In cytokine-primed eosinophils (IL-5, IL-33, GM-CSF):

  • Secondary crosslinking is no longer required

  • The cell death mechanism shifts to involve:

    • Mitochondrial damage

    • Reactive oxygen species (ROS) production

    • NADPH oxidase activation

    • Caspase-independent pathways

  • Requires CD11b/CD18 integrin-mediated adhesion

  • Involves signaling through Syk, PI3K, and PLC

Researchers can assess these mechanisms through:

• ROS detection using dihydrorhodamine 123 (DHR 123) loading followed by flow cytometry

• Surface CD11b expression measurement

• Cell death quantification via Annexin V/DAPI staining

• Specific pathway inhibition using pharmacological agents to confirm signaling requirements

How do cis interactions between Siglec-8 and endogenous sialylated ligands regulate its function?

Siglec-8 function is intrinsically regulated by interactions with sialylated cis ligands present on the same cell surface, a phenomenon with significant methodological implications for researchers:

• Masking effect: Siglec-8 is partially masked by interactions with sialylated ligands on human eosinophils and mast cells, which restrains its function .

• Sialic acid linkage specificity: These masking cis ligands specifically contain α2,3-linked sialic acid .

• Functional consequences:

  • Enzymatic removal of α2,3-linked sialic acid from the cell surface "licenses" Siglec-8 to cause cell death upon receptor ligation

  • This effect resembles the IL-5-licensed eosinophil death induction pathway

  • The phenomenon depends on the enzymatic activity of sialidase, not enhanced antibody binding

Researchers investigating Siglec-8 function should consider incorporating sialidase treatment in their experimental protocols to potentially enhance functional responses. This approach offers a promising strategy for selective depletion of both eosinophils and mast cells through Siglec-8 targeting .

How do different antibody formats affect Siglec-8-mediated cellular responses?

Different antibody formats demonstrate distinct functional profiles when targeting Siglec-8, which researchers should consider when designing experiments:

• IgG1 vs. IgG4 formats:

  • Chimeric 2E2 IgG1 (c2E2 IgG1) and chimeric 2E2 IgG4 are equally effective at inducing cell death (Annexin-V positivity) in IL-5-primed eosinophils from both normal donors and eosinophilic donors

  • Without IL-5 priming, cell death induction is observed only in eosinophils from eosinophilic donors

  • Natural killer cell-mediated eosinophil killing is observed only with c2E2 IgG1, suggesting Fc-dependent mechanisms

• Afucosylation effects:

  • Afucosylated IgG1 antibodies can enhance effector functions through improved FcγRIIIa binding

  • This modification can impact antibody-dependent cellular cytotoxicity (ADCC) potential

• In vivo translation:

  • Treatment of humanized mice with anti-Siglec-8 antibody results in robust depletion of IL-5-induced eosinophilia

Experimental design should account for these format-dependent effects, particularly when assessing antibody efficacy across different disease models or translating findings to in vivo systems.

What is the potential of Siglec-8 antibodies in treating non-allergic inflammatory conditions?

While Siglec-8 antibodies were initially investigated for allergic conditions, emerging research demonstrates significant efficacy in non-allergic inflammatory disorders:

• COPD model findings:

  • Anti-Siglec-8 treatment in a cigarette smoke (CS)-induced COPD model decreased airway inflammation

  • Weekly therapeutic dosing (starting at week 8 of a 12-week exposure protocol) was effective

  • Assessment of bronchoalveolar lavage (BAL) fluid revealed reduced inflammatory cell infiltration

• Lung fibrosis models:

  • In bleomycin (BLM)-induced lung injury models, anti-Siglec-8 treatment significantly:

    • Suppressed infiltration of neutrophils, monocytes, and macrophages

    • Reduced pro-inflammatory cytokines and chemokines (IL-6, CXCL1, IP-10)

    • Decreased lung fibrosis (assessed by Ashcroft score)

    • Lowered collagen and TGFβ levels in BAL fluid

• IL-33-mediated inflammation:

  • Anti-Siglec-8 treatment inhibits IL-33-mediated mast cell activation

  • It reduces neutrophil influx by modulating the mast cell transcriptome

  • The antibody reduces human neutrophil migration mediated by IL-33-activated human peripheral blood-derived mast cells

These findings expand the potential therapeutic applications of Siglec-8 antibodies beyond allergic diseases to conditions characterized by non-allergic inflammation and fibrosis, such as COPD and idiopathic pulmonary fibrosis.

What are the critical considerations for developing and validating Siglec-8-targeting therapeutic antibodies?

Researchers developing Siglec-8-targeting therapeutic antibodies should address these critical considerations:

• Expression stability assessment:

  • Quantify Siglec-8 expression levels on target cells across disease states

  • Evaluate expression following treatment with standard-of-care therapies

  • Determine expression differences between blood and tissue-resident cells

• Antibody specificity validation:

  • Confirm specificity using cross-reactivity assays against other Siglec family members

  • Verify binding to recombinant Siglec-8 protein

  • Test binding to cells expressing other Siglecs to exclude off-target effects

• Functional characterization:

  • Assess effects on:

    • Eosinophil viability (with/without cytokine priming)

    • Mast cell degranulation

    • Basophil activation

    • Cytokine/chemokine production

  • Evaluate both direct (cell death) and indirect (inflammatory mediator release) effects

• In vivo model selection:

  • Use appropriate humanized or transgenic mouse models expressing Siglec-8

  • Consider disease-specific models (allergic asthma, COPD, fibrosis)

  • Assess both preventative and therapeutic dosing regimens

• Biomarker development:

  • Develop assays for soluble Siglec-8 (sSiglec-8) detection

  • Correlate sSiglec-8 levels with disease activity and treatment response

  • Investigate potential impact of sSiglec-8 on antibody efficacy